Products & ReviewLife Sciences
Refametinib
MEK/ERK pathway inhibitor; Inhibits MEK1 and MEK2
Refametinib
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Refametinib is an inhibitor of both mitogen-activated protein kinase kinases 1 (MEK1) and 2 (MEK2) with IC₅₀ values of 19 and 47 nM respectively. It binds in an allosteric site adjacent to the ATP pocket and is selective for MEK1/2 versus 205 other kinases (Iverson et al.).
CANCER RESEARCH
- Inhibits growth of cancer cell lines in vitro, including those expressing B-RAF mutation V600E (Iverson et al.).
- Inhibits tumor growth in various xenograft models including human melanoma A375 and human colon cancer Colo205 cell lines, and primary pancreatic cancers (Iverson et al.; Chang et al.).
- Synergistically induces apoptosis in pancreatic cancer cell lines when combined with Erlotinib, an epidermal growth factor receptor (EGFR) inhibitor (Diep et al.).
- Synergistically inhibits tumor growth in hepatocellular carcinoma rodent models when combined with Sorafenib, an inhibitor of the tyrosine kinases vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR; Schmieder et al.).
